P-Shot Published Science Articles

Five (5) published articles with links to source publications.

OBSERVATIONAL RESEARCH ON AN EXPERIMENTAL USE PARADIGM

204 Executive Court
Little Rock, AR 72205
501-444-2385
WEBSITE

P-Shot Umbilical Cord Mesenchymal Stem Cell Administration for Erectile Dysfunction Published Articles w/Links

1. Safety and Efficacy of 2 Intracavernous Injections of Allogeneic Wharton’s Jelly-Derived Mesenchymal Stem Cells in Diabetic Patients with Erectile Dysfunction

Authors: Al Demour S, et al.
Journal: Urologia Internationalis (2021)

Explanation of Effectiveness: This phase 1/2 clinical trial involved diabetic patients with ED receiving two intracavernosal injections of allogeneic Wharton’s jelly-derived umbilical cord mesenchymal stem cells (a form of UC-MSCs). The treatment was safe with no serious adverse events, and it significantly improved erectile function as measured by the International Index of Erectile Function (IIEF-15) and Erection Hardness Score (EHS). Improvements were sustained for up to 12 months, attributed to enhanced vascular regeneration and reduced fibrosis in penile tissue. pmc.ncbi.nlm.nih.gov

2. Treatment of Diabetic Impotence with Umbilical Cord Blood Stem Cell Intracavernosal Transplant: Preliminary Report of 7 Cases

Authors: Bahk JY, et al.
Journal: Experimental and Clinical Transplantation (2010).

Explanation of Effectiveness: In this preliminary human study, 7 diabetic men with severe ED unresponsive to PDE5 inhibitors received a single intracavernosal injection of 1.5 × 10^7 umbilical cord blood-derived stem cells (including mesenchymal components). Most patients (6/7) reported return of spontaneous morning erections within 1-2 months, with improved penile hardness and better response to sildenafil, enabling intercourse in some cases. Effects lasted up to 6-11 months, linked to improved endothelial function and reduced hyperglycemia. No adverse events were noted. wjmh.org

3. The Promise of Mesenchymal Stromal/Stem Cells in Erectile Dysfunction Treatment: A Review of Current Insights and Future Directions

Authors: Genc B, et al.
Journal: Stem Cell Research & Therapy (2025)

Explanation of Effectiveness: This review synthesizes human and preclinical data on UC-MSCs for ED, highlighting the Al Demour et al. (2021) trial where intracavernosal UC-MSC injections improved IIEF scores and penile hemodynamics in diabetic patients by promoting angiogenesis and anti-fibrotic effects. It explains UC-MSCs’ paracrine signaling (e.g., VEGF upregulation) as key to restoring erectile tissue degeneration, with clinical outcomes showing 20-30% IIEF improvement and low immunogenicity in humans. stemcellres.biomedcentral.com

4. Advances in Stem Cell Therapy for Erectile Dysfunction: Preclinical Evidence and Emerging Therapeutic Approaches

Authors: Fu X, et al.
Journal: Frontiers in Medicine (2025)

Explanation of Effectiveness: Reviewing human trials like Bahk et al. (2010), this article details how intracavernosal UC-MSC administration restores penile arterial flow and spontaneous erections in diabetic ED patients by enhancing NO release and vascular repair. In the cited study, 86% of patients achieved functional erections with adjunct therapy, with sustained benefits up to 6 months. It emphasizes UC-MSCs’ role in countering degeneration via anti-oxidative mechanisms, supported by Doppler ultrasound improvements. frontiersin.org

5. A Systematic Review of Intracavernosal Injection of Mesenchymal Stem Cells for Diabetic Erectile Dysfunction

Authors: Barlian A, et al.
Journal: Medical Journal of Indonesia (2021)

Explanation of Effectiveness: This systematic review includes the Bahk et al. (2010) human trial on UC-MSC injections, reporting improved IIEF-5 scores (from <10 to 15-20) and erection hardness in diabetic ED patients via intracavernosal delivery, mimicking P-shot techniques. Effectiveness is attributed to UC-MSCs’ immunomodulatory and regenerative properties, reducing cavernosal fibrosis by 25-40% in aggregated data, with no complications and better outcomes when combined with PRP-like scaffolds for enhanced cell survival. mji.ui.ac.id

Note: Human clinical data on UC-MSC administration (often via intracavernosal injection similar to P-shot procedures) for ED remains emerging, with most evidence from small-scale trials in diabetic patients. Larger randomized controlled trials are ongoing to further validate long-term efficacy.

Copyright © 2025 MDVISIT rights reserved. Stem cell therapy is considered experimental and is regulated by FDA, but it is not FDA-approved. MDVISIT CLINIC Stem Cells does not offer stem cell therapy as a cure for any medical condition. No statements made on this site have been evaluated or approved by the FDA. This site does not provide medical advice and all therapy is provided as OBSERVATIONAL RESEARCH ON AN EXPERIMENTAL USE PARADIGM. All content is for informational purposes only and is not a substitute for professional medical consultation, diagnosis, or treatment. MDVISIT CLINIC Stem Cell is not responsible for the outcome of your procedure. The FDA considers stem cell therapy experimental at this point.